Polyclonal Ki-67 expression in transitional cell carcinoma of the bladder

Area of Science:

• Uro-oncology
• Immunohistochemistry
• Cancer Biology

Background:

• Transitional cell carcinoma (TCC) is the most common type of bladder cancer.
• Accurate assessment of tumor behavior and progression is crucial for effective clinical management.
• Proliferation markers can provide insights into tumor kinetics.

Purpose of the Study:

• To evaluate the proliferation kinetics of transitional cell carcinoma (TCC) using the Ki-67 antibody (pKi-67).
• To determine the association between pKi-67 labeling indices and clinicopathological parameters of bladder TCC.
• To assess the utility of pKi-67 as a marker for tumor progression in TCC.

Main Methods:

• Immunohistochemical staining with polyclonal Ki-67 antibody (pKi-67) was performed on 101 cases of TCC and 7 cases of TCC-in-situ.
• Labeling indices (LI) were calculated for each case.
• Statistical analysis was used to correlate pKi-67 LI with tumor grade, stage, and invasion front morphology.

Main Results:

• Mean pKi-67 LI was 22.2%, with a range of 49% to 60.2%.
• Significant associations were found between pKi-67 LI, tumor grade (Grade 1 vs. 3, Grade 2 vs. 3), and tumor stage (superficial Ta vs. muscle-invasive T2/T3a and T3b).
• pKi-67 LI for carcinoma-in-situ were comparable to Grade 1 TCC.

Conclusions:

• The pKi-67 index is a significant marker for assessing tumor progression in vesical TCC.
• Immunohistochemical assessment of pKi-67 can assist clinicians in evaluating the potential behavior of individual bladder tumors.
• pKi-67 may serve as a valuable prognostic indicator in TCC management.